Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sembragiline

Next Previous
X
Search
Drug Profile

Sembragiline

Alternative Names: EVT-302; RG-1577; RO-4602522

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Evotec SE; Roche
  • Class Acetanilides; Nootropics; Pyrrolidines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Smoking withdrawal

Most Recent Events

  • 08 Sep 2016 Phase II development is ongoing in Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Korea, Spain, Sweden, United Kingdom and USA (Evotec pipeline, September 2016)
  • 30 Jun 2015 Interim efficacy and safety data from a phase-II trial in Alzheimer's disease released by Roche (NCT01677754)
  • 22 Jun 2015 No recent reports on development identified - Phase-I for Alzheimer's disease (In volunteers) in Netherlands (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top